Literature DB >> 7301675

Satalol-induced torsade de pointes.

A Kontopoulos, A Filindris, F Manoudis, P Metaxas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7301675      PMCID： PMC2424931          DOI： 10.1136/pgmj.57.667.321

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  9 in total

Review 1.  Adverse reactions to beta-blocking drugs: a review.

Authors:  J C Petrie; D B Galloway; T A Jeffers; J Webster
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

2.  Torsade De Pointes, an atypical ventricular tachycardia.

Authors:  D M Krikler; P V Curry
Journal:  Br Heart J       Date:  1976-02

3.  Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias.

Authors:  E Elonen; P J Neuvonen; L Tarssanen; R Kala
Journal:  Br Med J       Date:  1979-05-05

4.  Tropical splenomegaly syndrome.

Authors: 
Journal:  Br Med J       Date:  1971-02-20

5.  Fatal oxprenolol poisoning.

Authors:  A Khan; J M Muscat-Baron
Journal:  Br Med J       Date:  1977-02-26

6.  Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.

Authors:  R S Meltzer; E W Robert; M McMorrow; R P Martin
Journal:  Am J Cardiol       Date:  1978-12       Impact factor: 2.778

7.  A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474.

Authors:  B N Singh; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

8.  Disopyramide-induced ventricular fibrillation.

Authors:  W J Nicholson; C E Martin; J G Gracey; H R Knoch
Journal:  Am J Cardiol       Date:  1979-05       Impact factor: 2.778

9.  Polymorphous ventricular tachycardia: clinical features and treatment.

Authors:  S Sclarovksy; B Strasberg; R F Lewin; J Agmon
Journal:  Am J Cardiol       Date:  1979-08       Impact factor: 2.778
  9 in total
  11 in total

Review 1.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 2.  Assessment of the risk-benefit ratio for antiarrhythmic drug use.

Authors:  R W Campbell
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 3.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Electrophysiological effects of sotalol--just another beta blocker?

Authors:  A W Nathan; K J Hellestrand; R S Bexton; D E Ward; R A Spurrell; A J Camm
Journal:  Br Heart J       Date:  1982-06

5.  The combined electrophysiological effects of lignocaine and sotalol in canine isolated cardiac Purkinje fibres are rate-dependent.

Authors:  D A Lathrop; A Varró
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 6.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Sotalol, hypokalaemia, syncope, and torsade de pointes.

Authors:  J K McKibbin; W A Pocock; J B Barlow; R N Millar; I W Obel
Journal:  Br Heart J       Date:  1984-02

Review 8.  Class III antiarrhythmics in overdose. Presenting features and management principles.

Authors:  E W Leatham; D W Holt; W J McKenna
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 9.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 10.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.